precision-medicine
(158)
Vertex Pharmaceuticals and the art of starting over
A hepatitis C blockbuster disappeared. A cystic fibrosis franchise took its place. Now Vertex is spending billions to see how often it can repeat the trick.
nference Wants Medicine to Read Its Own Notes
Hospitals have spent decades recording what happens to patients. nference is building the machinery to turn those scattered records into evidence - without asking hospitals to surrender control.
A2 Biotherapeutics teaches cancer fighters when to stop
A missing genetic marker is usually a gift to cancer. A2 Biotherapeutics is turning that absence into a target, with engineered T cells designed to attack tumors and spare healthy tissue.
Superluminal Medicines is betting on proteins that refuse to sit still
The Boston biotech designs drugs for receptors in motion. A Lilly partnership and a coming obesity trial will test how much that extra dimension is worth.
Magnet Biomedicine wants to give difficult proteins a useful introduction
Some proteins resist a drug’s advances. Magnet Biomedicine is recruiting a second protein to help - a molecular matchmaking strategy that has attracted $50 million in venture funding and an oncology agreement with Lilly.
Lifebit wants to move medicine forward. The data stays put.
The hard part of genomic research is often getting permission to use what already exists. Lifebit sends the tools to the data, turning institutional boundaries into something a researcher can work across.
Curve Biosciences Is Teaching a Blood Test Where to Look
Blood carries DNA from all over the body. Curve Biosciences is building a tissue atlas to sort out the return addresses, starting with chronic liver disease.
Precede Biosciences asks what cancer is doing now
A milliliter of plasma can carry clues to a tumor’s working life. Precede Biosciences is turning those clues into research tools for the medicines that need more than a mutation report.
PathAI’s big bet on the humble tissue slide
Roche agreed to pay $750 million upfront for a company that teaches computers to examine tissue. PathAI’s more revealing achievement is building a place where those computers and pathologists can work together.
Perspectum wants your MRI to put a number on disease
An Oxford spin-out turns MRI scans into measurements of organ health. Its harder task is proving that better numbers lead to better decisions - and are worth paying for.
Ontada finds cancer evidence in the everyday
The oncology business inside McKesson turns routine patient records into research material. Its advantage begins where the treatment happens - and its hardest work begins where the tidy fields end.
Seven Bridges and the Genome That Stayed Put
The clever move in genomics was to stop moving the data. Seven Bridges built a business bringing researchers, workflows and rented computing power to the same place - and now carries that idea into Velsera.
Magnus and the fifty-minute pause
A five-day depression treatment sounds like a story about speed. Magnus Medical’s SAINT system makes a more interesting wager: where you stimulate the brain, and when you stop, can matter as much as how hard you try.
The Button That Asked Medicine to Remember
Atropos Health began with a Stanford physician’s question: what can the records of past patients teach us about the person in front of us? Its answer grew from a 48-hour consult into a system that puts real-world evidence inside clinical and research workflows.
The Trial Is Open. Why Can’t the Patient Get In?
Trial Library has built a business around an awkward truth in cancer care: a trial can exist, a patient can qualify, and the two may still never meet. Its answer starts with the oncologist and continues long after the search result.
Biostate AI Made the Data Cheaper. Then the Data Became the Problem.
A Houston biotech cut the cost of reading RNA, only to find its scientists swamped by the results. The tool it built to catch up may be the more revealing business.
The Drug Targets Hiding in Plain Sight
BridGene built a way to watch drug-like molecules meet proteins inside living cells. The wager is that the so-called undruggable proteome is not impossible - merely badly observed.
The Tiny Lymph Nodes Making a Very Large Bet
Parallel Bio grows repeatable human immune systems in dishes, lets robots run the experiments, and asks a blunt question: why wait for a clinical trial to learn that mice are not people?
The Weight-Loss Company Betting the Answer Is Not Just a Drug
Ilant Health began with a surprisingly ordinary failure: a patient had to find her own obesity care. Now it is trying to turn treatment matching, human support and financial accountability into one coherent benefit.
GeneOnline Turned Biotech News Into a Map for Finding the Next Deal
The bilingual publisher spent years explaining Asian biotech to the world. Then it packaged the map behind the reporting into BIODND - an AI-assisted database built for the people hunting companies, capital and partners.
CareDx Made Transplant Care Less Invasive. Then Its Own Business Needed Surgery.
The transplant diagnostics company turned fragments of donor DNA into a recurring-care business. A 2023 reimbursement shock forced a reset - and revealed a playbook built on narrow markets, repeat tests, and one very deep customer relationship.
Incyclix Bio Is Betting One Precise Brake Can Stop Cancer's Second Escape Route
A 13-person North Carolina biotech licensed an overlooked CDK2 program, narrowed the patient target and pushed one oral drug into the clinic. Early data offer a reason to keep going - and a useful blueprint for building around a precise scientific thesis rather than a sprawling pipeline.
The Cancer Drug Isn’t Broken. Navrogen Thinks the Tumor Is Blocking the Signal
A tiny Pennsylvania biotech is betting that some antibody therapies fail for a surprisingly fixable reason: tumors throw molecular sand in the gears. Its answer is to redesign the antibody - or remove the sand.
Faeth Bet $92 Million That Cancer’s Escape Route Can Be Blocked
Single-target cancer drugs can teach tumors how to route around them. Faeth’s answer is PIKTOR - two oral medicines, three pathway nodes and a public-company-sized test of whether deeper blockade can stay tolerable.
The $85 Million Bet That a DNA Scaffold Can Make Gene Therapy Re-Dosable
Code Biotherapeutics is trying to turn DNA into the FedEx network for genetic medicine. Its modular 3DNA scaffold promises bigger payloads, precise addresses and repeat delivery - but the public evidence is still preclinical.
Delve Bio Built One Test for 68,000 Suspects - Now It Wants Doctors to Use It Before the Guessing Game
The UCSF spinout turned an academic pathogen-hunting assay into a 48-hour clinical service. Its next challenge is bigger than sequencing: persuading hospitals to order one broad test earlier, without pretending every strange read is the answer.
Lantern Laboratory Wants Anesthesia to Read the Brain - Not Just the Room
A tiny New York medtech is betting that anesthesia needs more than one reassuring number. Its EEG platform tries to separate sleep, pain and cognitive age - and an early trial shows exactly how hard that promise will be to prove.
The Chicago lab teaching hospitals to read your blood before sepsis reads you
Sepsis kills more Americans than all cancers combined and hides in plain sight. Prenosis spent a decade building a biobank and an algorithm to catch it in the first 24 hours - and got the FDA to say yes.
The Biotech Betting That Cancer Drugs Fail Because Nobody Looked at the Proteins
80% of cancer compounds that reach clinical trials fail. Yatiri Bio thinks the problem is that drug developers have been reading the wrong molecules - and it built a proteomics platform to prove it.
The Birmingham startup that made pharma pay for trust it never earned
Del Smith and Tiffany Whitlow built a 200,000-member community first and an AI second - and got seven of the ten biggest drug makers to buy the trust they earned.